**FOI Ref: 6399**

**Category(ies): Clinical - Drugs**

**Subject: Intra-vitreal treatments in Ophthalmology**

**Date Received: 19/05/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| I am researching the usage of high-cost intra-vitreal treatments in Ophthalmology. Your answers to the following questions will be highly appreciated |
| 1. How many patients over the last 4 months (January to April 2022) have received the following anti-VEGF treatments for any eye condition:* Aflibercept
* Bevacizumab
* Brolucizumab
* Dexamethasone
* Ranibizumab
 | * Aflibercept – 792
* Bevacizumab – 0
* Brolucizumab – 0
* Dexamethasone – 3
* Ranibizumab – 1040
 |
| 2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.* Aflibercept
* Bevacizumab
* Brolucizumab
* Dexamethasone
* Ranibizumab
 | * Aflibercept – 46
* Bevacizumab – 0
* Brolucizumab – 0
* Dexamethasone – 0
* Ranibizumab – 60
 |
| 3. Please provide the number of patients treated for Diabetic Macular Oedema (DMO) ONLY in the last 4 months (January to April 2022) with the following: * Aflibercept
* Bevacizumab
* Dexamethasone
* Ranibizumab
 |

|  |  |
| --- | --- |
|   | **Eye Conditions** |
| **Treatment** | Diabetic Macular Degeneration DMO |
| Aflibercept  | 201 |
| Bevacizumab  |  0  |
| Dexamethasone   |  0  |
| Ranibizumab  |  232  |

 |
| 4. Please provide the number of patients treated for Retinal Vein Occlusion (RVO) ONLY in the last 4 months (January to April 2022) with the following: * Aflibercept
* Bevacizumab
* Dexamethasone
* Ranibizumab
 |

|  |  |
| --- | --- |
|   | **Eye Conditions** |
| **Treatment** | Retinal Vein Occulusion RVO |
| Aflibercept  |  179 |
| Bevacizumab  |  0 |
| Dexamethasone   |  3  |
| Ranibizumab  |  229  |

 |